Harris Kenner
Cardiovascular Disease · Chevy Chase, MDNPI 1558368464
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,572 and has fallen 83.3% since, to $262 in 2022.
Across 156 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$429
- Johnson & Johnson$391
- Boehringer Ingelheim$349
- Pfizer$275
- Daiichi Sankyo Inc.$265
- Sanofi-aventis U.S. LLC$218
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,109100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 19 | $429 |
| Johnson & Johnson | 16 | $391 |
| Boehringer Ingelheim | 14 | $349 |
| Pfizer | 14 | $275 |
| Daiichi Sankyo Inc. | 14 | $265 |
| Sanofi-aventis U.S. LLC | 15 | $218 |
| Amarin Pharma, Inc. | 12 | $207 |
| Novartis | 10 | $180 |
| Abbott | 3 | $124 |
| E.r. Squibb & Sons, L.L.C. | 9 | $116 |
| Bayer | 3 | $64 |
| Boston Scientific | 2 | $62 |
| Esperion Therapeutics, Inc. | 3 | $61 |
| AbbVie(2 entities) | 3 | $57 |
| Lundbeck LLC | 3 | $56 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Astellas Pharma US Inc | 2 | $40 |
| Novo Nordisk | 2 | $36 |
| AstraZeneca | 2 | $30 |
| Tactile Systems Technology Inc | 2 | $23 |
| IBSA Pharma Inc. | 1 | $20 |
| Edwards Lifesciences | 1 | $18 |
| Gilead | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$3,109 in reported general payments places this provider in the 60th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Chevy Chase
- Richard RubinChevy Chase$42K
- Ankit ShahChevy Chase$35K
- Jack FlyerChevy Chase$19K
- Robert MarshallChevy Chase$15K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.